|
|
To: APIXABAN |
To: EDOXABAN | To: RIVAROXABAN | To: DABIGATRAN |
| Switching from: DABIGATRAN |
Stop dabigatran Start apixaban when next dose of dabigatran was due |
Stop dabigatran Start edoxaban when next dose of dabigatran was due |
Stop dabigatran CrCL ≥50 mL/min: start rivaroxaban 24 hours after last dose of dabigatran. CrCL 30 to 49mL/min: start rivaroxaban 48 hours after last dose of dabigatran. CrCL <30mL/min: start rivaroxaban 3 to 4 days after last dose of dabigatran. |
⊗ |
|
Switching from: |
Stop rivaroxaban Start apixaban when next dose of rivaroxaban was due |
Stop rivaroxaban Start edoxaban when next dose of rivaroxaban was due |
⊗ |
Stop rivaroxaban Start dabigatran 24 hours after last rivaroxaban dose |
| Switching from: EDOXABAN |
Stop edoxaban Start apixaban when next dose of edoxaban was due |
⊗ |
Stop edoxaban Start rivaroxaban when next dose of edoxaban was due |
Stop edoxaban Start dabigatran when next dose of edoxaban was due |
|
Switching from: FORMULARY FIRST LINE CHOICE |
⊗ |
Stop apixaban Start edoxaban when next dose of apixaban was due |
Stop apixaban Start rivaroxaban when next dose of apixaban was due |
Stop apixaban Start dabigatran when next dose of apixaban was due |
Anticoagulant switching (Guidelines)
Warning
What's new / Latest updates
08/12/25 v2.1: The term 'unfractionated heparin' is changed to 'heparin' as per BNF update.
This information is to provides a reasonable starting point for most patients but the clinical background of each patient must be considered before applying the guidance.
If unsure, seek specialist advice.
- The guidance only applies to patients receiving anticoagulation for prophylaxis for stroke and systemic embolism in non-valvular AF or patients treated for DVT and prevention of recurrent DVT and PE.
- For other indications, or for high-risk patients (such as those with artificial heart valves or those with target INRs above 3·0), seek specialist advice.
- Prescribers should check the BNF or SPC for further information on prescribing for each individual drug.
- Usually there is no need for parenteral anticoagulants when initiating oral anticoagulants in patients with atrial fibrillation only.